title: Combination of TLR1/2 and TLR3 ligands enhances CD4(+) T cell longevity and antibody responses by modulating type I IFN production.
abstract: Despite the possibility of combining Toll-like receptor (TLR) ligands as adjuvants to improve vaccine efficacy, it remains unclear which combinations of TLR ligands are effective or what their underlying mechanisms may be. Here, we investigated the mechanism of action of L-pampo, a proprietary adjuvant composed of TLR1/2 and TLR3 ligands. L-pampo dramatically increased humoral immune responses against the tested target antigens, which was correlated with an increase in follicular helper T cells and the maintenance of antigen-specific CD4(+) T cells. During the initial priming phase, in contrast to the induction of type I interferon (IFN) and pro-inflammatory cytokines stimulated by polyI:C, L-pampo showed a greatly diminished induction of type I IFN, but not of other cytokines, and remarkably attenuated IRF3 signaling, which appeared to be critical to L-pampo-mediated adjuvanticity. Collectively, our results demonstrate that the adjuvant L-pampo contributes to the promotion of antigen-specific antibodies and CD4(+) T cell responses via a fine regulation of the TLR1/2 and TLR3 signaling pathways, which may be helpful in the design of improved vaccines.
authors: Department of Biochemistry, College of Life Science &Biotechnology, Yonsei University, Seoul 120749, Republic of Korea.
authors: Bo Ryeong
authors: BR
authors: Lee
authors: R&D Center, CHA Vaccine Institute, Seongnam-si, Gyeonggi 462716, Republic of Korea.
authors: Soo Kyung
authors: SK
authors: Jeong
authors: R&D Center, CHA Vaccine Institute, Seongnam-si, Gyeonggi 462716, Republic of Korea.
authors: Byung Cheol
authors: BC
authors: Ahn
authors: Jeonbuk Department of Inhalation Research, Korea Institute of Toxicology, Jeollabuk-do 56212, Republic of Korea.
authors: Byeong-Jae
authors: BJ
authors: Lee
authors: Department of Microbiology, Institute for Immunology and Immunological Diseases, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul 120749, Republic of Korea.
authors: Sung Jae
authors: SJ
authors: Shin
authors: R&D Center, CHA Vaccine Institute, Seongnam-si, Gyeonggi 462716, Republic of Korea.
authors: Jung Sun
authors: JS
authors: Yum
authors: Department of Biochemistry, College of Life Science &Biotechnology, Yonsei University, Seoul 120749, Republic of Korea.
authors: Sang-Jun
authors: SJ
authors: Ha
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D019264:Adoptive Transfer; D000818:Animals; D000941:Antigens / Q000008:administration & dosage; D005786:Gene Expression Regulation; D056724:Immunity, Humoral / Q000187:drug effects*; D007114:Immunization; D007370:Interferon Type I / Q000235:genetics / Q000276:immunology*; D008024:Ligands; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D010047:Ovalbumin / Q000008:administration & dosage; D011070:Poly I-C / Q000008:administration & dosage; D000067996:RAW 264.7 Cells; D006377:T-Lymphocytes, Helper-Inducer / Q000166:cytology / Q000187:drug effects / Q000276:immunology* / Q000637:transplantation; D051194:Toll-Like Receptor 1 / Q000235:genetics / Q000276:immunology*; D051195:Toll-Like Receptor 2 / Q000235:genetics / Q000276:immunology*; D051196:Toll-Like Receptor 3 / Q000235:genetics / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D000941:Antigens; D007370:Interferon Type I; D008024:Ligands; C519703:TLR3 protein, mouse; C493486:Tlr2 protein, mouse; D051194:Toll-Like Receptor 1; D051195:Toll-Like Receptor 2; D051196:Toll-Like Receptor 3; D010047:Ovalbumin; D011070:Poly I-C